About
Batea Oncology develops GlioHook, a class III medical device implanted after glioblastoma surgery to concentrate residual tumor cells and enhance their sensitivity to radiotherapy, aiming to reduce tumor infiltration and improve patient survival.
Explore Batea Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.